Physician profile
Mohammed Abdul Hadi
NPI 1427111764
$5,358.67
in general payments reported to CMS, 2019-2025
23 companies · $696 in 2025
The $696 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $890 · 2021: $387 · 2022: $909 · 2023: $1,243 · 2024: $659 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,598.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,950.30 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $749.49 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $491.03 | 2021-2025 | |
| Lilly USA, LLC | $370.88 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Sumitomo Pharma America, INC. | $270.14 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $254.98 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $230.36 | 2021-2022 | |
| Novo Nordisk INC | $190.65 | 2022-2025 | Rybelsus, Ozempic |
| Amgen INC. | $150.65 | 2023-2025 | Evenity, Krystexxa, Repatha |
| Merck Sharp & Dohme LLC | $126.83 | 2019-2020 | |
| Allergan, INC. | $93.11 | 2019-2020 | |
| Pfizer INC. | $85.47 | 2022 | |
| Shield Therapeutics INC | $72.40 | 2025 | |
| Janssen Pharmaceuticals, INC | $68.22 | 2019-2020 | |
| Eisai INC. | $62.50 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.11 | 2022 | |
| Inogen, INC. | $32.17 | 2021 | |
| Horizon Therapeutics Plc | $27.32 | 2021 | |
| Lundbeck LLC | $23.08 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $22.07 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $21.83 | 2024 | Rexulti |
| Amryt Pharma Holdings LTD | $18.33 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Hadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.